Abstract
Introduction: Distant metastases and especially single side metastases of non-muscle invasive bladder cancer (NMIBC) without regional progression in lymph nodes are extremely uncommon and rare. Case Presentation: We report a case of a plasmacytoid and sarcomatoid differentiated urothelial NMIIC with a single metastasis to the right ventricle of the heart, which was surgically resected, but the patient died shortly after the resection with progressive metastatic disease. To the best of our knowledge, this is the first case with two different variant histologies in NMIBC with a single heart metastasis. Furthermore, we conducted a rapid review using MEDLINE regarding single heart metastasis of bladder cancer. Four cases have been identified. Interestingly, with 2 cases of variant histology and one with single plasmacytoid differentiation, also being NMIBC. Conclusion: These findings underline the aggressiveness of the variant histologies in NMIBC, especially plasmacytoid differentiation, and may favor an early and aggressive treatment regimen. Further scientific research concerning the optimal treatment of histologically variant bladder cancer is absolutely needed.
Journal Section:
Case Report
References
1.
Siegel
RL
, Giaquinto
AN
, Jemal
A
. Cancer statistics, 2024
. CA Cancer J Clin
. 2024
;74
(1
):12
–49
. 2.
Halaseh
SA
, Halaseh
S
, Alali
Y
, Ashour
ME
, Alharayzah
MJ
. A review of the etiology and epidemiology of bladder cancer: all you need to know
. Cureus
. 2022
;14
(7
):e27330
. 3.
Sung
H
, Ferlay
J
, Siegel
RL
, Laversanne
M
, Soerjomataram
I
, Jemal
A
, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
. 4.
Safiri
S
, Kolahi
AA
, Naghavi
M
; Global Burden of Disease Bladder Cancer Collaborators
. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019
. BMJ Glob Health
. 2021
;6
(11
):e004128
. 5.
Saginala
K
, Barsouk
A
, Aluru
JS
, Rawla
P
, Padala
SA
, Barsouk
A
. Epidemiology of bladder cancer
. Med Sci
. 2020
;8
(1
):15
. 6.
Compérat
E
, Larré
S
, Roupret
M
, Neuzillet
Y
, Pignot
G
, Quintens
H
, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old
. Virchows Arch
. 2015
;466
(5
):589
–94
. 7.
EAU Guidelines
. Presented at the EAU Annual Congress Paris
. Arnhem, The Netherlands
: EAU Guidelines Office
; 2024
. https://uroweb.org/guidelines8.
Xu
T
, Gu
W
, Wang
X
, Xia
L
, He
Y
, Dong
F
, et al. Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature
. World J Surg Oncol
. 2022
;20
(1
):226
. 9.
Matthews
PN
, Madden
M
, Bidgood
KA
, Fisher
C
. The clinicopathological features of metastatic superficial papillary bladder cancer
. J Urol
. 1984
;132
(5
):904
–6
. 10.
Al-Mamgani
A
, Baartman
L
, Baaijens
M
, de Pree
I
, Incrocci
L
, Levendag
PC
. Cardiac metastases
. Int J Clin Oncol
. 2008
;13
(4
):369
–72
. 11.
Bussani
R
, De-Giorgio
F
, Abbate
A
, Silvestri
F
. Cardiac metastases
. J Clin Pathol
. 2007
;60
(1
):27
–34
. 12.
Butany
J
, Leong
SW
, Carmichael
K
, Komeda
M
. A 30-year analysis of cardiac neoplasms at autopsy
. Can J Cardiol
. 2005
;21
(8
):675
–80
.13.
Ramlawi
B
, Leja
MJ
, Abu Saleh
WK
, Al Jabbari
O
, Benjamin
R
, Ravi
V
, et al. Surgical treatment of primary cardiac sarcomas: review of a single-institution experience
. Ann Thorac Surg
. 2016
;101
(2
):698
–702
. 14.
Yanagawa
B
, Latter
D
, Verma
S
. Year in review: mitral valve surgery
. Curr Opin Cardiol
. 2016
;31
(2
):148
–53
. 15.
Haby
MM
, Chapman
E
, Clark
R
, Barreto
J
, Reveiz
L
, Lavis
JN
. What are the best methodologies for rapid reviews of the research evidence for evidence-informed decision making in health policy and practice: a rapid review
. Health Res Policy Syst
. 2016
;14
(1
):83
. 16.
Liberati
A
, Altman
DG
, Tetzlaff
J
, Mulrow
C
, Gøtzsche
PC
, Ioannidis
JPA
, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
. J Clin Epidemiol
. 2009
;62
(10
):e1
–34
. 17.
Stricker
PD
, Grant
AB
. Solitary metastasis of squamous cell carcinoma of the bladder to the myocardium
. J Urol
. 1987
;137
(1
):113
–4
. 18.
Spiliotopoulos
K
, Argiriou
M
, Argyrakos
T
, Haritopoulos
K
, Kanakakis
K
, Sakellaridis
T
, et al. Solitary metastasis of urothelial carcinoma of the urinary bladder to the heart: an unusual clinical manifestation
. J Thorac Cardiovasc Surg
. 2008
;136
(5
):1377
–8.e1
. 19.
Mountzios
G
, Bamias
A
, Dalianis
A
, Danias
P
, Pantelidaki
E
, Nanas
J
, et al. Endocardial metastases as the only site of relapse in a patient with bladder carcinoma: a case report and review of the literature
. Int J Cardiol
. 2010
;140
(1
):e4
–7
. 20.
Peck
JR
, Hitchcock
CL
, Maguire
S
, Dickerson
J
, Bush
C
. Isolated cardiac metastasis from plasmacytoid urothelial carcinoma of the bladder
. Exp Hematol Oncol
. 2012
;1
:16
. 21.
Wallmeroth
A
, Wagner
U
, Moch
H
, Gasser
TC
, Sauter
G
, Mihatsch
MJ
. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients
. Urol Int
. 1999
;62
(2
):69
–75
. 22.
Gu
L
, Ai
Q
, Cheng
Q
, Ma
X
, Wang
B
, Huang
Q
, et al. Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes
. Cancer Cell Int
. 2020
;20
(1
):550
. 23.
Diamantopoulos
LN
, Korentzelos
D
, Alevizakos
M
, Wright
JL
, Grivas
P
, Appleman
LJ
. Sarcomatoid urothelial carcinoma: a population-based study of clinicopathologic characteristics and survival outcomes
. Clin Genitourin Cancer
. 2022
;20
(2
):139
–47
. 24.
Sui
W
, Matulay
JT
, Onyeji
IC
, Theofanides
MC
, James
MB
, RoyChoudhury
A
, et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer
. World J Urol
. 2017
;35
(7
):1055
–61
. 25.
Mai
KT
, Park
PC
, Yazdi
HM
, Saltel
E
, Erdogan
S
, Stinson
WA
, et al. Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases
. Eur Urol
. 2006
;50
(5
):1111
–4
. 26.
Al-Ahmadie
HA
, Iyer
G
, Lee
BH
, Scott
SN
, Mehra
R
, Bagrodia
A
, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer
. Nat Genet
. 2016
;48
(4
):356
–8
. 27.
Messina
C
, Zanardi
E
, Dellepiane
C
, Tomasello
L
, Colecchia
M
, Ravetti
GL
, et al. A case of plasmacytoid variant of bladder cancer with a single penile metastasis and a complete response to carboplatin-based chemotherapy and review of the literature
. Clin Genitourin Cancer
. 2016
;14
(1
):e139
–42
. 28.
Horwich
A
, Babjuk
M
, Bellmunt
J
, Bruins
HM
, De Reijke
TM
, De Santis
M
, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an International Collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
. Ann Oncol
. 2019
;30
(11
):1697
–727
. 29.
Vetterlein
MW
, Wankowicz
SAM
, Seisen
T
, Lander
R
, Löppenberg
B
, Chun
FKH
, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology
. Cancer
. 2017
;123
(22
):4346
–55
. 30.
Genitsch
V
, Kollár
A
, Vandekerkhove
G
, Blarer
J
, Furrer
M
, Annala
M
, et al. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer
. Urol Oncol
. 2019
;37
(9
):573.e19
–29
. 31.
Powles
T
, Valderrama
BP
, Gupta
S
, Bedke
J
, Kikuchi
E
, Hoffman-Censits
J
, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
. N Engl J Med
. 2024
;390
(10
):875
–88
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
